Ironwood Pharmaceuticals: A Leading Small-Cap Drug Manufacturer With Promising Growth Prospects

Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) is one of the best small-cap drug manufacturing stocks to buy, according to hedge funds. The company reported in-line Q4 results and reaffirmed its 2026 outlook, including adjusted EBITDA of over $300M. LINZESS-related headwinds appear to have eased, positioning the company to generate meaningful cash flow and fund future growth initiatives. Ironwood is focused on maximizing LINZESS and advancing apraglutide while sustaining profits and cash flows.